QUIMIOTERAPIA NOS TUMORES DE MАМА AXILA-NEGATIVA
Abstract
In the period of january of 1983 to december of 1990, were diagnosed and treated 72 consecutive cases of breast cancer having a diameter of 2cm or less and histologicaly negative axillary nodes in the instituto de Ginecologia da Fundação Pioneiras Sociais - RJ.
In thirteen patients (Group 1) the tumoral diameter was less than 1cm (18%); in 27 (37,5%) it was between 1.1. to 1.5cm (Group 2) and in 32 (44.4%) it was to 1.6 to 2. cm (Group 3).
The follow-up time was 64.4 months (M = 68).
The parameters for analysis were the size of tumor, histologic grade, menopausal status and type of primary therapy. The disease-free survival rate (DFS) for the group was of 97.1% at 5 and 9 years and the overall survival (OS), 100% and 91% at 5 and 9 years
respectively.
Considering the size of the tumor, all the patients of Group 1 were alive and disease-free at 9 years; Group 2 had 96.2% of DFS and 100% of OS and 78% of Group 3 patients were alive and 96.7% disease-free in the same period.
Taking into consideration the histologic grade, 97.8% of well differentiated (GI), 100% of moderately differentiated (GII) and 87.5% of poorly differentiated tumors (GIII) were disease-free at 9 years. The OS was 92% for the GI, 100% for GII and 83.3% for GIII tumors (p = 0.657).
The menopausal status and primary treatment hasn't modified the prognosis. These data, according to the literature sugests that patients having a tumoral diameter of less than 1cm and well-differentiated are highly curable by surgical and radiotherapic therapy. The authors believe that these patients are not appropriate candidates for adjuvant chemotherapy until new prognostic factors have been well established.
Downloads
References
ANDERSEN, J. A. et alii. Selection of
nigh risk Group Among prognostically
favorable patients with breast cancer. Annals of Surgery, 194 (1): 1-3,
1981.
2. BELANGER, D. et alii. How American
Oncologists treat breast cancer: An
assessment of the influence of clinical trials. J. Clin. Oncol., 9(1): 7-16,
1991.
3. BONADONNA, G. Conceptual and practical advances in the management of
breast cancer. J. Clin. Oncol., 7
(10): 1380-7, 1989.
4. CADY, B. New diagnostic, staging and
therapeutic aspects of early breastcancer. Cancer, 65 (1): 634-47, 1990.
5. CLAYTON, F. Pathologic correlates of
survival in 378 lymph node-negative
infiltrating ductal breast cancer. Cancer, 68 (6): 1309-17, 1991.
6. CONTESSO, G. et. alii. The importance of histologic grade in long-term
prognosis of breast cancer: A study
of 1010 patients, Uniformly treated at
Institut Gustave-Roussy. J. of Clin.
Oncol., 5 (2): 1378-86, 1987.
7. COOPER, M.R. The role of chemotherapy fornode-negative breast cancer. Cancer, 67 (6): 1744-7, 1991.
Suppl.
8. FISHER, B. et alii. A randomized clinical trial evaluating sequencial
methotrexate and fluoracil in the treatment of patients with node-negative
breast cancer who have estrongenreceptor-negative tumors. Vew Engl.
J. Medicine, 320 (8): 473-8, 1989.
9.A randomized clinical trial
evaluating tamoxifen in the treatment
of patients with node-negative breast
cancer who have estrogen-receptorpositive tumors. New Engl. J. Medicine, 320 (8): 479-84, 1989.
10. Tumor nuclear grade,
estron receptorand progesterone receptor: Their value alone or in combination as indicator of outcome following adjuvant therapy for breast
cancer. Breast Cancer Res. Treatment, (7): 147-160, 1986.
11.Relative worth of estrogen or progesterone receptor and
pathologic characteristic of
diferentiation as indicators of prognosis in node negative breast cancer
patients: Findings from NSABP B-06.
J. Clin. Oncol., 6 (7): 1076-87, 1988
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Fabíola Tonial, Olímpio F. Neto, Oscar G. Freire, Sérgio Bicalho
This work is licensed under a Creative Commons Attribution 4.0 International License.
